{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"NWBO","limit":50},"count":50,"signals":[{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"00,000,000 to 2,600,000,000. For Proposal No. 4, the affirmative vote of a majority of the votes cast with respect to such matter is required to approve, on an advisory basis, the compensation of our named executive officers.  With respect to routine matters, a bank, brokerage firm, or other nominee has the authority (but is not required) to vote its clients shares if the clients do not provide instructions. When a bank","filed_date":"2025-11-28","accession":"0001104659-25-116966","full_text":"https://origin.rootz.global/static/filing/0001104659-25-116966.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"o development and/or approval of competing products, lack of funding, and/or other factors. In addition, our Phase III trial of DCVax-L was placed on a partial clinical hold for new screening for enrollment in 2015. Although the FDA lifted its hold in February2017 as previously reported by the Company, the Company had already closed enrollment with 331 of the planned 348 patients. Since we did not en","filed_date":"2025-03-31","accession":"0001410578-25-000598","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, m","filed_date":"2025-03-31","accession":"0001410578-25-000598","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"She also earned a J.D., magna cum laude, from Harvard Law School. We believe Ms. Powers background and experience make her well qualified to serve as a Director. *J. Cofer Black.*Ambassador Black was appointed to the Board of Directors in January 2016. Ambassador Black is an internationally renowned U.S. government leader and expert in cybersecurity, counterterrorism and national security. In addition to serving on company and ban","filed_date":"2025-03-31","accession":"0001410578-25-000598","full_text":"https://origin.rootz.global/static/filing/0001410578-25-000598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the fiscal year ending December31, 2024;  3. To ratify the same option awards that were made in 2020 to the named executive officers and for which the stockholders already voted in favor in an advisory vote at the 2021 Annual Meeting and in a ratification vote at the 2022 Annual Meeting;  4. To ratify the same option awards that","filed_date":"2024-06-03","accession":"0001104659-24-067885","full_text":"https://origin.rootz.global/static/filing/0001104659-24-067885.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"She also earned a J.D., magna cum laude, from Harvard Law School. We believe Ms.Powers background and experience make her well qualified to serve as a Director. *J. Cofer Black.*Ambassador Black was appointed to the Board of Directors in January2016. Ambassador Black is an internationally renowned U.S. government leader and expert in cybersecurity, counterterrorism and national security. In addition to serving on company and bank","filed_date":"2024-04-29","accession":"0001104659-24-054153","full_text":"https://origin.rootz.global/static/filing/0001104659-24-054153.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, m","filed_date":"2024-03-05","accession":"0001410578-24-000133","full_text":"https://origin.rootz.global/static/filing/0001410578-24-000133.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"o development and/or approval of competing products, lack of funding, and/or other factors. In addition, our Phase III trial of DCVax-L was placed on a partial clinical hold for new screening for enrollment in 2015. Although the FDA lifted its hold in February2017 as previously reported by the Company, the Company had already closed enrollment with 331 of the planned 348 patients. Since we did not en","filed_date":"2023-02-28","accession":"0001410578-23-000185","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":21,"context":"5 |  |  |  | |  PROPOSAL NO. 2RATIFICATION OF APPOINTMENT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |  |  |  |  |  8 |  |  |  | |  PROPOSAL NO. 3RATIFICATION OF THE SAME OPTION AWARDS TO NAMED EXECUTIVE OFFICERS THAT WERE MADE IN 2020 AND FOR WHICH STOCKHOLDERS ALREADY VOTED IN FAVOR IN AN ADVISORY VOTE AT LAST YEARS ANNUAL MEETING |  |  |  |  |  9 |  |  |  | |  PROPOSAL NO. 4APPROVAL, ON AN ADVISORY BASIS,","filed_date":"2022-12-05","accession":"0001104659-22-124360","full_text":"https://origin.rootz.global/static/filing/0001104659-22-124360.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"o development and/or approval of competing products, lack of funding, and/or other factors. In addition, our Phase III trial of DCVax-L was placed on a partial clinical hold for new screening for enrollment in 2015. Although the FDA lifted its hold in February 2017 as previously reported by the Company, the Company had already closed enrollment with 331 of the planned 348 patients. Since we did not e","filed_date":"2019-04-02","accession":"0001144204-19-017803","full_text":"https://origin.rootz.global/static/filing/0001144204-19-017803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, m","filed_date":"2019-04-02","accession":"0001144204-19-017803","full_text":"https://origin.rootz.global/static/filing/0001144204-19-017803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"her well qualified to serve as a Director. * * *Alton L. Boynton, Ph.D.* Dr. Boynton co-founded our Company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003, and served as Chief Executive Officer from June 2007 to June 2011. Prior to founding our Company, Dr. Boynton headed the Molecular Oncology resear","filed_date":"2019-04-02","accession":"0001144204-19-017803","full_text":"https://origin.rootz.global/static/filing/0001144204-19-017803.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ncers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. The Company is also working on preparations for Phase II trials of DCVax-L for other indications. Our second product, DCVax-Direct, is designed to treat inoperable solid tumors. A 40-pa","filed_date":"2018-04-17","accession":"0001144204-18-020971","full_text":"https://origin.rootz.global/static/filing/0001144204-18-020971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"qualified to serve as a Director. | | 31 | | | *Alton L. Boynton, Ph.D.* Dr. Boynton co-founded our Company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003, and served as Chief Executive Officer from June 2007 to June 2011. Prior to founding our Company, Dr. Boynton headed the Molecular Oncology resear","filed_date":"2018-04-17","accession":"0001144204-18-020971","full_text":"https://origin.rootz.global/static/filing/0001144204-18-020971.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"make her well qualified to serve as a Director.  Alton L. Boynton, Ph.D. Dr.Boynton co-founded our Company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August2001, was appointed President in May2003, and served as Chief Executive Officer from June2007 to June2011. Prior to founding our Company, Dr.Boynton headed the Molecular Oncology research la","filed_date":"2018-01-09","accession":"0001174947-18-000017","full_text":"https://origin.rootz.global/static/filing/0001174947-18-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"of the UK Mortgage with the applicable filing office, the Lenders Lien in the Collateral will be a second priority fully perfected Lien on the Collateral, subject to no Liens except Permitted Liens. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). New Notes means the convertible notes to be issued by","filed_date":"2017-06-27","accession":"0001144204-17-034437","full_text":"https://origin.rootz.global/static/filing/0001144204-17-034437.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"l have the meaning ascribed to such term in Section 3.1(p). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other material restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Participation Maximum shall have the meaning ascribed","filed_date":"2017-05-31","accession":"0001144204-17-030281","full_text":"https://origin.rootz.global/static/filing/0001144204-17-030281.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"nce | |  | 17,776 | | |  | 48,242 | | | |  Income tax provision (benefit) | |  $ | - | | |  $ | - | | | **14. Subsequent Events** ** ** *Registered Direct Offering* * * On March 17, 2017, the Company entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million. The Company sold approximately 18.8 million shares of common stock at a purchase price of $0.26 per","filed_date":"2017-04-17","accession":"0001144204-17-020754","full_text":"https://origin.rootz.global/static/filing/0001144204-17-020754.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"the election and, accordingly, will not affect the election of directors. **Proposal 2: Advisory Votes on 2013 Executive Compensation** The approval, on an advisory basis, of the compensation of our Named Executive Officers (as defined below) as disclosed in this proxy statement requires the affirmative vote of the holders of a majority of the shares of our common stock present or represented and entitled to vote on th","filed_date":"2014-11-26","accession":"0001174947-14-000519","full_text":"https://origin.rootz.global/static/filing/0001174947-14-000519.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"ake her well qualified to serve as a Director. *Alton L. Boynton, Ph.D.* Dr. Boynton co-founded our company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003, and served as Chief Executive Officer from June 2007 to June 2011. Prior to founding our company, Dr. Boynton headed the Molecular Oncology resear","filed_date":"2013-12-03","accession":"0001174947-13-000398","full_text":"https://origin.rootz.global/static/filing/0001174947-13-000398.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"program, we will have to obtain substantial amounts of further funding. Our ongoing funding requirements will depend on many factors, including the number of staff we employ, the pace of patient enrollment in our brain cancer trial, the cost of establishing clinical studies and compassionate use/named patient programs in other countries, and unanticipated developments. Without additional capital, we","filed_date":"2012-12-04","accession":"0001144204-12-066236","full_text":"https://origin.rootz.global/static/filing/0001144204-12-066236.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"ly stage trials in multiple other diverse cancers. As of June 29, 2012, our Phase III clinical trial in GBM is being conducted at more than 40 sites in the United States, and is expected to begin enrollment by July or August 2012 in the United Kingdom and Germany. Our DCVax immunotherapies are based on a platform technology involving dendritic cells, the master cells of the immune system, and are des","filed_date":"2012-06-29","accession":"0001144204-12-037417","full_text":"https://origin.rootz.global/static/filing/0001144204-12-037417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"he study generates results similar to those achieved in the two prior clinical trials. We currently have 13 clinical sites that are qualified and ready to enroll patients.In order to enable rapid enrollment, we may add some additional clinical sites for this trial when resources permit. We are engaged in discussions with the FDA concerning the study design and end points. Depending on trial results,","filed_date":"2011-04-21","accession":"0001144204-11-023452","full_text":"https://origin.rootz.global/static/filing/0001144204-11-023452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"|  | Alton L. Boynton, Ph.D. Dr. Boynton co-founded the Company, has served as Secretary since August 2001, has served as our Chief Scientific Officer and a director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003 and was appointed Chief Executive Officer in June 2007. Dr. Boynton has also served as Director of the Department of Molecular Medicine of Northwes","filed_date":"2011-04-21","accession":"0001144204-11-023452","full_text":"https://origin.rootz.global/static/filing/0001144204-11-023452.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"he study generates results similar to those achieved in the two prior clinical trials. We currently have 13 clinical sites that are qualified and ready to enroll patients.In order to enable rapid enrollment, we may add some additional clinical sites for this trial when resources permit. We are engaged in discussions with the FDA concerning the study design and end points. Depending on trial results,","filed_date":"2010-04-15","accession":"0001144204-10-020547","full_text":"https://origin.rootz.global/static/filing/0001144204-10-020547.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"r |  | Alton L. Boynton, Ph.D.Dr. Boynton co-founded the Company, has served as Secretary since August 2001, has served as our Chief Scientific Officer and a director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003 and was appointed Chief Executive Officer in June 2007. Dr. Boynton has also served as Director of the Department of Molecular Medicine of Northwes","filed_date":"2010-04-15","accession":"0001144204-10-020547","full_text":"https://origin.rootz.global/static/filing/0001144204-10-020547.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":": |  |  |  each person, or group of affiliated persons, who is known by us to own beneficially 5% or more of any class of our equity securities; |  | |  |  |  our directors; |  | |  |  |  each of our named executive officers, as defined in Item402(a)(3) of RegulationS-K;and |  | |  |  |  our directors and executive officers as a group. |  | The applicable percentages of ownership are based on an aggregate of 45,069,872s","filed_date":"2009-08-06","accession":"0001144204-09-040745","full_text":"https://origin.rootz.global/static/filing/0001144204-09-040745.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"240patients and is designed to enable us to petition the FDA for accelerated approval if the study generates results similar to those achieved in earlier Phase I studies. In order to enable rapid enrollment, we are in the process of enrolling 45 to 50 additional clinical sites for this trial. As of January 1, 2009, thirteensites are active and a further 31 sites are at various stages of the start-up","filed_date":"2009-04-15","accession":"0001144204-09-020743","full_text":"https://origin.rootz.global/static/filing/0001144204-09-020743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"tor |  | Alton L. Boynton,Ph.D.Dr.Boynton co-founded the Company, has served as Secretary since August 2001, has served as our Chief Scientific Officer and a director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003 and was appointed Chief Executive Officer in June 2007. Dr.Boynton has also served as Director of the Department of Molecular Medicine of Northwest","filed_date":"2009-04-15","accession":"0001144204-09-020743","full_text":"https://origin.rootz.global/static/filing/0001144204-09-020743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"ach person, or group of affiliated persons, who is known by us to own beneficially 5% or more of any class of our equity securities; |  | | | | |  |  |  our directors; |  | | | | |  |  |  each of our named executive officers, as defined in Item402(a)(3) of RegulationS-K;and |  | | | | |  |  |  our directors and executive officers as a group. |  | The applicable percentages of ownership are based on an aggregate of 42,34","filed_date":"2008-05-14","accession":"0000950134-08-009517","full_text":"https://origin.rootz.global/static/filing/0000950134-08-009517.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"240patients and is designed to enable us to petition the FDA for accelerated approval if the study generates results similar to those achieved in earlier Phase I studies. In order to enable rapid enrollment, we are in the process of enrolling 45 to 50 additional clinical sites for this trial. As of April9, 2008, seven sites are active and a further 31 sites are at various stages of the start-up proce","filed_date":"2008-04-15","accession":"0000891020-08-000094","full_text":"https://origin.rootz.global/static/filing/0000891020-08-000094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"r |  | *Alton L. Boynton,Ph.D.*Dr.Boynton co-founded the Company, has served as Secretary since August 2001, has served as our Chief Scientific Officer and a director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May 2003 and was appointed Chief Executive Officer in June 2007. Dr.Boynton has also served as Director of the Department of Molecular Medicine of Northwest","filed_date":"2008-04-15","accession":"0000891020-08-000094","full_text":"https://origin.rootz.global/static/filing/0000891020-08-000094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"o assurance that the Companys efforts to seek such funding will be successful. If the Companys capital raising efforts are unsuccessful, its inability to obtain additional cash as needed could have a material adverse effect on the Companys financial position, results of operations and its ability to continue its existence. The Companys independent registered public accounting firm has indicated in their report on the fi","filed_date":"2007-11-14","accession":"0001362310-07-002999","full_text":"https://origin.rootz.global/static/filing/0001362310-07-002999.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"o assurance that the Companys efforts to seek such funding will be successful. If the Companys capital raising efforts are unsuccessful, its inability to obtain additional cash as needed could have a material adverse effect on the Companys financial position, results of operations and its ability to continue its existence. The Companys independent auditors have indicated in their report on the financial statements, incl","filed_date":"2007-08-20","accession":"0001362310-07-001941","full_text":"https://origin.rootz.global/static/filing/0001362310-07-001941.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"s or obligations) (the Maximum Issuance), in one or more tranches. |  | |  |  |  | |  First Closing: |  First closing (First Closing) to occur upon completion of Bridge Period, documentation and fulfillment of conditions to closing. |  | |  |  |  | |  Subsequent Closings: |  Additional closings of the Convertible Preferred Stock after the First Closing (Subsequent Closings) may take place at any time","filed_date":"2004-12-02","accession":"0001145443-04-001947","full_text":"https://origin.rootz.global/static/filing/0001145443-04-001947.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"), and the other related recapitalization documents must be true and correct as of each closing; |  | |  |  |  |  | |  |  |  No change may have occurred that has had or is reasonably likely to have a material adverse effect on our business, affairs, prospects, operations, properties, assets, liabilities, structure or condition, financial or otherwise (as our business is presently conducted and/or as it is proposed to be","filed_date":"2004-12-02","accession":"0001145443-04-001947","full_text":"https://origin.rootz.global/static/filing/0001145443-04-001947.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"such financing, or that the terms of such financings will be attractive to us. If the Companys capital raising efforts are unsuccessful, its inability to obtain additional cash as needed could have a material adverse effect on the Companys financial position, results of operations and its ability to continue in existence. Its independent registered public accounting firm has indicated in its report on the Companys conso","filed_date":"2009-11-23","accession":"0001144204-09-061567","full_text":"https://origin.rootz.global/static/filing/0001144204-09-061567.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"such financing, or that the terms of such financings will be attractive to us. If the Companys capital raising efforts are unsuccessful, its inability to obtain additional cash as needed could have a material adverse effect on the Companys financial position, results of operations and its ability to continue in existence. Its independent registered public accounting firm has indicated in its report on the Companys conso","filed_date":"2009-08-14","accession":"0001144204-09-043686","full_text":"https://origin.rootz.global/static/filing/0001144204-09-043686.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"lete any such financings or that the terms of such financings will be attractive to us. If our capital raising efforts are unsuccessful, our inability to obtain additional cash as needed could have a material adverse effect on our financial position, results of operations and our ability to continue our existence. Our independent registered public accounting firm has indicated in its report on our consolidated financial","filed_date":"2008-11-19","accession":"0001362310-08-007500","full_text":"https://origin.rootz.global/static/filing/0001362310-08-007500.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"ete any such financings, or that the terms of such financings will be attractive to us. If our capital raising efforts are unsuccessful, our inability to obtain additional cash as needed could have a material adverse effect on our financial position, results of operations and our ability to continue our existence. Our independent registered public accounting firm has indicated in its report on our consolidated financial","filed_date":"2008-08-19","accession":"0001362310-08-004766","full_text":"https://origin.rootz.global/static/filing/0001362310-08-004766.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"ete any such financings, or that the terms of such financings will be attractive to us. If our capital raising efforts are unsuccessful, our inability to obtain additional cash as needed could have a material adverse effect on our financial position, results of operations and our ability to continue our existence. Our independent registered public accounting firm has indicated in its report on our consolidated financial","filed_date":"2008-05-15","accession":"0001362310-08-002857","full_text":"https://origin.rootz.global/static/filing/0001362310-08-002857.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":98,"match_count":11,"context":"magna cum laude, from Harvard Law School. We believe Ms. Powers background and experience make her well qualified to serve as a Director. 33 [Table of Contents](#TOC) *Dr. Navid Malik*.Dr. Malik was appointed to the Board of Directors in April 2012. Dr. Malik is currently Head of Research and an Executive Director at The Life Sciences Division, a UK Investment Bank (since 2018). From January 2012 to December 2015, Dr. Malik was p","filed_date":"2023-02-28","accession":"0001410578-23-000185","full_text":"https://origin.rootz.global/static/filing/0001410578-23-000185.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":96,"match_count":12,"context":"ing, assuming a quorum is present. For Proposal No. 2, the affirmative vote of a majority of the votes cast at the Annual Meeting is required to approve, on an advisory basis, the compensation of our Named Executive Officers. For Proposal No. 3, the affirmative vote of a majority of the votes cast at the Annual Meeting is required to ratify the appointment of Cherry Bekaert LLP as our independent registered public accou","filed_date":"2021-04-16","accession":"0001104659-21-051466","full_text":"https://origin.rootz.global/static/filing/0001104659-21-051466.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"of doctors and patients have become aware of DCVax and the prior clinical trial results, and are actively seeking access to DCVax treatments. So, the Company believes there is a clear pathway to enrollment of the remaining patients, as long as sufficient funding is available. **Prostate Cancer** Prostate cancer is the most common cancer in men in the U.S., accounting for more than 25% of all cancers","filed_date":"2012-04-13","accession":"0001144204-12-021574","full_text":"https://origin.rootz.global/static/filing/0001144204-12-021574.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":95,"match_count":10,"context":"es her well qualified to serve as a Director.  *Alton L. Boynton, Ph.D*. Dr. Boynton co-founded our company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May, 2003, and served as Chief Executive Officer from June, 2007, to June, 2011. Prior to founding our company, Dr. Boynton headed the Molecular Oncology re","filed_date":"2012-12-04","accession":"0001144204-12-066236","full_text":"https://origin.rootz.global/static/filing/0001144204-12-066236.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":94,"match_count":8,"context":"ncings, or that the terms of such financings will be attractive to the Company. If the Companys capital raising efforts are unsuccessful,its inability to obtain additional cash as needed could have a material adverse effect on the Companys financial position, results of operations and the Companys ability to continueits existence. The Companys independent registered public accounting firm has indicated in its report on","filed_date":"2009-05-20","accession":"0001144204-09-028693","full_text":"https://origin.rootz.global/static/filing/0001144204-09-028693.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":90,"match_count":10,"context":"kes her well qualified to serve as a Director. *Alton L. Boynton, Ph.D.* Dr. Boynton co-founded our company, has served as our Chief Scientific Officer and a Director since our inception in 1998, was appointed our Chief Operating Officer in August 2001, was appointed President in May, 2003, and served as Chief Executive Officer from June, 2007, to June, 2011. Prior to founding our company, Dr. Boynton headed the Molecular Oncology re","filed_date":"2012-06-29","accession":"0001144204-12-037417","full_text":"https://origin.rootz.global/static/filing/0001144204-12-037417.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":89,"match_count":8,"context":"use of the DCVax name in Europe would require us to market our potential products in Europe under a different name which could impair the successful marketing of our product candidates and may have a material adverse effect on our results of operations and financial condition. Competing generic medicinal products may be approved. In the E.U., there exists a process for the approval of generic biological medicinal produc","filed_date":"2009-04-15","accession":"0001144204-09-020743","full_text":"https://origin.rootz.global/static/filing/0001144204-09-020743.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":89,"match_count":8,"context":"use of the DCVax name in Europe would require us to market our potential products in Europe under a different name which could impair the successful marketing of our product candidates and may have a material adverse effect on our results of operations and financial condition. **Competing generic medicinal products may be approved.** In the E.U., there exists a process for the approval of generic biological medicinal pr","filed_date":"2008-04-15","accession":"0000891020-08-000094","full_text":"https://origin.rootz.global/static/filing/0000891020-08-000094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"NWBO","company":"NORTHWEST BIOTHERAPEUTICS INC","exchange":"OTC","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ncers in which the tumor can be surgically removed. This product in an ongoing Phase III trial for newly diagnosed Glioblastome multiforme (GBM). 331 patients have been enrolled in the trial, and enrollment is closed. The Company is also working on preparations for Phase II trials of DCVax-L for other indications. Our second product, DCVax-Direct, is designed to treat inoperable solid tumors. A 40-pa","filed_date":"2017-04-17","accession":"0001144204-17-020754","full_text":"https://origin.rootz.global/static/filing/0001144204-17-020754.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"764ef866b39328e3599476dcabad9f24d04d865d0a9dfb59dc9fa45c8923c5cb","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"1499da45af84791e295922b1a22e37a6d34f25018f0d273d84f9c42a9b56ba8d","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":80,"hourly_limit":500,"remaining":420,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}